Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623 1693
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18014705 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | Non-Final OA | The Regents of the University of California |
| 19323247 | TRANS-CYCLOOCTENE PRODRUG OF MONOMETHYL AURISTATIN E | Non-Final OA | TAMBO, INC. |
| 17624625 | TRANS-CYCLOOCTENE BIOORTHOGONAL AGENTS AND USES IN CANCER AND IMMUNOTHERAPY | Non-Final OA | Tambo, Inc. |
| 18449727 | COMPOSITE SOLUTION FOR ENHANCING INDUCED DISEASE RESISTANCE OF LENTINAN (LNT) TO PLANT, PREPARATION METHOD OF COMPOSITE SOLUTION, AND METHOD FOR ENHANCING INDUCED DISEASE RESISTANCE OF LNT TO PLANT | Non-Final OA | China Agricultural University |
| 17904907 | COMPOSITION AND METHOD TO PREPARE LONG-ACTING INJECTABLE SUSPENSION CONTAINING MULTIPLE CANCER DRUGS | Non-Final OA | University of Washington |
| 18001655 | THERAPEUTIC TREATMENT USING PROTEIN KINASE C (PKC) INHIBITORS AND CYTOTOXIC AGENTS | Non-Final OA | Cambridge Enterprise Limited |
| 18026009 | AUTOPHAGY ACTIVATOR | Non-Final OA | Resonac Corporation |
| 17250952 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 17772848 | METHOD FOR MANUFACTURING REVAUDIOSIDE-D-CONTAINING CRYSTALLIZED PRODUCT, AND REVAUDIOSIDE-D-CONTAINING CRYSTALLIZED PRODUCT | Non-Final OA | SUNTORY HOLDINGS LIMITED |
| 17772872 | METHOD FOR MANUFACTURING REVAUDIOSIDE-D-CONTAINING CRYSTALLIZED PRODUCT, AND REVAUDIOSIDE-D-CONTAINING CRYSTALLIZED PRODUCT | Non-Final OA | SUNTORY HOLDINGS LIMITED |
| 18229838 | SIZE SELECTION PURIFICATION USING A THERMOPLASTIC SILICA NANOMATERIAL | Non-Final OA | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. |
| 17784474 | RAPID PRECIPITATION-DRIVEN KILOBASE SIZE SELECTION OF HMW DNA | Final Rejection | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. |
| 18284991 | CYTOKINE PRODUCTION SUPPRESSING COMPOSITION CONTAINING D-ALLOSE AS ACTIVE COMPONENT, AND METHOD OF TREATING OR PREVENTING DISEASE ASSOCIATED WITH CYTOKINE OVERPRODUCTION USING SAME | Non-Final OA | SETOLAS HOLDINGS, INC. |
| 18560456 | APPLICATION OF ALGINATE OLIGOSACCHARIDES | Non-Final OA | HAITANG (JIANGSU) BIOTECHNOLOGY COMPANY, LTD. |
| 17791851 | NEW IMMUNOSTIMULATORS AND USE THEREOF IN IMMUNOTHERAPY | Non-Final OA | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) |
| 18552139 | COMPOSITIONS COMPRISING TOPIRAMATE FOR TREATING DERMATOLOGICAL CONDITIONS | Non-Final OA | Sabina GLOZMAN |
| 18550853 | Prevention and Treatment of Periodontal and Peri-Implant Disease | Non-Final OA | LABRIDA AS |
| 17620612 | METHOD FOR ENRICHING NUCLEIC ACIDS BY SIZE | Non-Final OA | QIAGEN GmbH |
| 18006479 | AMINOACIDS FOR TREATMENT OF NEUROLOGICAL DISORDERS | Non-Final OA | ScandiBio Therapeutics AB |
| 18000200 | NUCLEIC ACID EXTRACTION METHOD AND APPLICATION | Non-Final OA | NUHIGH BIOTECHNOLOGIES CO., LTD. |
| 17785711 | CROSS-LYNKED HYALURONIC ACID SYNTHESIS PROCESS | Non-Final OA | ISTITUTO GANASSINI S.P.A. DI RICERCHE BIOCHIMICHE |
| 17835363 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND THE USE THEREOF | Final Rejection | GALECTIN SCIENCES, LLC |
| 17769522 | CYCLODEXTRIN-BASED GAMMALINOLENIC ACID FORMULATION FOR TREATMENT OF BRAIN CANCER | Non-Final OA | SEFACOR INC. |
| 17623554 | INHALABLE COMPOSITION COMPROMISING CYCLODEXTRIN FOR USE IN THE TREATMENT OF NASAL INFLAMMATIONS | Non-Final OA | AQUILON PHARMACEUTICALS SA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy